



**Bihar Medical Services & Infrastructure Corporation  
Limited**

**4<sup>th</sup> floor State Building Construction Corporation  
Limited. Hospital Road, Shastri Nagar, Patna  
800023**

**Phone/Fax: +917008050665, + 919471009193**

**CORRIGENDUM-II**

**Short Tender for rate contract and supply of Drugs used after Kidney Transplant for  
different healthcare facilities of State of Bihar for the year 2019-21**

**Notice Inviting Tender Ref No.: - BMSIC/DRUGS/19-11**

**Dated:24-12-2019**

(Only through E- Tender on website: -[www.eproc.bihar.gov.in](http://www.eproc.bihar.gov.in))

Bihar Medical Services and Infrastructure Corporation Limited (BMSICL) invites E-Bids from the interested parties for "**Short Tender for rate contract and supply of Drugs used after Kidney Transplant for different healthcare facilities of State of Bihar**", vide Notice Inviting Tender No.-BMSIC/DRUGS/19-11. Detailed tender document containing eligibility criteria, selection mechanism, other terms and conditions are available on the website [www.eproc.bihar.gov.in](http://www.eproc.bihar.gov.in).

All the suggestions /queries received from the prospective bidders during and after Pre-Bid meeting and the technical aspects were reviewed by the Technical Specification Committee (TSC) in its meeting dated 06-12-2019. The Minutes of the TSC meeting is attached here with along with this Corrigendum-II. The floated bid document is amended hereby in accordance with the attached minutes of the TSC meeting.

The Financial bid sheet has also been amended accordingly. Those Bidders who have already submitted their bids should also have to Re-submit their bids accordingly.

In order to give sufficient time and to ensure wider participation of the bidders the Tender Schedule is being revised as follows:-

**Revised Tender Schedule**

Tender Reference No.	<b>BMSIC/DRUGS/19-11</b>
Date and time for downloading of bid document	<b>Upto 07<sup>th</sup> January 2020 till 1500 Hrs.</b>
Last date and time of submission of online bids	<b>Upto 08<sup>th</sup> January 2020 by 18:00 Hrs.</b>
Last date and time for submission of original bid documents with EMD and Tender Fees	<b>Upto 10<sup>th</sup> January 2020 till 14:00 Hrs.</b>
Date, Time and Place of opening of Technical Bid	<b>Upto 10<sup>th</sup> January 2020 (at 15:00 Hrs.) on the website of <a href="http://www.eproc.bihar.gov.in">www.eproc.bihar.gov.in</a> in the office of BMSICL</b>
Date and time of opening of Financial Bids	<b>To be announced later on <a href="http://www.bmsicl.gov.in">www.bmsicl.gov.in</a> and <a href="http://www.eproc.bihar.gov.in">www.eproc.bihar.gov.in</a></b>
Validity of Tender	<b>180 Days</b>
Cost of the tender document	<b>Rs. 10,000/- (Ten Thousand only) Non-refundable.</b>
Bid Processing Fee	<b>Rs 1180/-(One thousand one hundred eighty only) Non-refundable.</b>

**Sd/-  
CGM (Supply Chain)  
BMSICL**

**Minutes of the Technical Specification Committee Meeting for Finalization of Technical Specification of Drugs floated vide tender no.- BMSIC/DRUGS/19-11 (Tender for rate Contract & Supply of Drugs used after kidney transplant for different healthcare facilities of State of Bihar for the year 2019-21.**

**Date: 06<sup>th</sup> December 2019**

**Venue: BMSICL Conference Hall.**

The Technical Specification Committee Meeting for finalization of the specification of the drugs floated vide tender no.- **BMSIC/DRUGS/19-11** was held on 06<sup>th</sup> December 2019 under the Chairmanship of Dr. Ashok Kumar, Director in Chief, Department of Health, GoB. The other committee members present in the meeting were:

1. Sh. Khalid Arshad, Administrative Officer, SHS Bihar.
2. Sh. Rajani Kant, CGM (Supply Chain), BMSICL.
3. Dr. Yashwant Singh, HoD Department of Nephrology, PMCH.
4. Dr. Ganesh Prasad, Department of Medicine, PMCH.
5. Sh. Sunil Kumar Singh, GM (Procurement), BMSICL.
6. Dr. Biswaprakash Pradhan, DGM (Drugs), BMSICL.
7. Sh. Ravi Kiran Rakesh, Manager (Drugs), BMSICL.

During and after pre-bid meeting held on 13<sup>th</sup> November 2019, various suggestion from prospective bidders were received. All the received suggestion and technical aspects were discussed in today's meeting. After due deliberations on all the aspects, it was unanimously decided to recommend to make certain amendments and clarifications as given in Annexure-A (clarification/ amendment), Annexure- B (revised tendered product list) and Annexure- C (revised format for enlisting the list of items quoted) of this minute of the meeting.

The onus lies on the bidder to provide its market standing through the performance statement (Self Declaration) to be submitted by the bidder as contained in Annexure- D. This statement shall be in addition to the Market Standing Certificate obtained by the bidder from the concerned competent authority.

**The meeting was thus concluded with a vote of thanks.**

**Sd/-**  
**(Ravi Kiran Rakesh)**  
Manager (Drugs), BMSICL, Patna.

**Sd/-**  
**(Dr. Biswaprakash Pradhan)**  
DGM (Drugs), BMSICL, Patna.

**Sd/-**  
**(Sunil Kumar Singh)**  
GM (Logistics), BMSICL, Patna

**Sd/-**  
**(Dr. Yashwant Singh)**  
Department of Nephrology,  
PMCH, Patna.

**Sd/-**  
**(Dr. Ganesh Prasad)**  
Department of Medicine, PMCH,  
Patna.

**Sd/-**  
**(Rajani Kant)**  
CGM (Supply Chain), BMSICL,  
Patna.

**Sd/-**  
**(Khalid Arshad)**  
Administrative Officer, SHS Bihar.

**Sd/-**  
**(Dr. Ashok Kumar)**  
Director in Chief, Health Dept. Govt. of Bihar.

**ANNEXURE-B****REVISED TENDERED PRODUCT LIST**

<b>BMSIC/DRUGS/19-11</b>					
<b>FY 2019-2021</b>					
<b>S.N.</b>	<b>Name of the Product</b>	<b>Specification / Strength</b>	<b>Dosage Form</b>	<b>Pack Size</b>	<b>Estimated tendered quantity (In Basic Unit) (<u>per tablet/ per capsule/per bottle/per pack/per vial etc.</u>)</b>
<b>1.</b>	Tacrolimus	0.5 mg	Capsule	10 X 10	<b>242000</b>
<b>2.</b>	Tacrolimus	1 mg	Capsule	10 X 10	<b>242000</b>
<b>3.</b>	Tacrolimus	2 mg	Capsule	10 X 10	<b>242000</b>
<b>4.</b>	Cyclosporine	25 mg	Capsule	10 X 10	120960
<b>5.</b>	Cyclosporine	50 mg	Capsule	10 X 10	120960
<b>6.</b>	Cyclosporine	100 mg	Capsule	10 X 10	60480
<b>7.</b>	Cyclosporine	100 mg/ ml	Solution	50 ml pack	10
<b>8.</b>	Everolimus	0.25 mg	Tablet	10 X 10	<b>36288</b>
<b>9.</b>	Everolimus	0.5 mg	Tablet	10 X 10	<b>36288</b>
<b>10.</b>	Everolimus	0.75 mg	Tablet	10 X 10	<b>36288</b>

<b>11.</b>	Everolimus	5 mg	Tablet	10 X 10	<b>36288</b>
<b>12.</b>	Everolimus	10 mg	Tablet	10 X 10	<b>36288</b>
<b>13.</b>	Mycophenolate Mofitel/ Mycophenolate Sodium	250 mg	Tablet	10 X 10	<b>181500</b>
<b>14.</b>	Mycophenolate Mofitel/ Mycophenolate Sodium	360 mg	Tablet	10 X 10	<b>181500</b>
<b>15.</b>	Mycophenolate Mofitel/ Mycophenolate Sodium	500 mg	Tablet	10 X 10	<b>181500</b>
<b>16.</b>	Esomeprazole	20 mg	Gastro- resistant Tablet	10 X 10	10000
<b>17.</b>	Esomeprazole	30 mg	Gastro- resistant Tablet	10 X 10	10000
<b>18.</b>	Esomeprazole	40 mg	Gastro- resistant Tablet	10 X 10	10000
<b>19.</b>	Labetalol (Beta Blockers)	100 mg	Tablet	10 X 10	10000
<b>20.</b>	Prazosin (Alpha Blockers)	2.5 mg	Tablet	10 X 10	10000
<b>21.</b>	Prazosin (Alpha Blockers)	5 mg	Tablet	10 X 10	10000
<b>22.</b>	Valganciclovir	450 mg	Tablet	1 x 4	2000
<b>23.</b>	Gancyclovir	500 mg/ vial	Injection	vial	2000
<b>24.</b>	Gancyclovir	100 mg/ ml	Oral Solution	30ml Bottle	2000

<b>25.</b>	Acyclovir	200 mg	Tablet	10 X 10	2000
<b>26.</b>	Acyclovir	400 mg	Tablet	10 X 10	2000
<b>27.</b>	Vancyclovir	500 mg	Tablet	10 X 10	2000
<b>28.</b>	Famcyclovir	250 mg	Tablet	10 X 10	2000
<b>29.</b>	Famcyclovir	500 mg	Tablet	10 X 10	2000
<b>30.</b>	Antithymocyte Globulins	100 mg	Injection	Vial	1000
<b>31.</b>	Antithymocyte Globulins	250mg`	Injection	Vial	1000
<b>32.</b>	Rituximab	100 mg/vial	Injection	Vial	1000
<b>33.</b>	Bortezumab	2.5 mg	Injection	Vial	1000
<b>34.</b>	Bortezumab	3.5 mg	Injection	Vial	1000

BMSIC/DRUGS/19-11 ANNEXURE-A				
BMSIC/DRUGS/19-11, Clarification in the light of queries/suggestions received from various firms during and after Pre-Bid Meeting held on 13/11/2019				
S. N.	Name of the Firm	Bidders Queries	Present Clause	Clarification/ Amendment
1	M/s Khandelwal Laboratories Pvt Ltd.	We would like to request you to make changes to (S. no- 35 - Bortezomib 2.5 mg Injection) as most of companies manufacture Bortezomib 2 mg Injection and most of the corporations procure 2 mg such as : 1. Odhisa Corporation 2. Rajasthan Corporation 3. M.P Corporation 4.Tamil Nadu Corporation 5. NHM Assam	<b>Annexure 1</b> List of the item quoted NIT Sl no.35 Bortezumab 2.5 mg Injection	No Change
2	M/s Dr. Reddy's Laboratories Ltd.	We would like to bring to your notice that in above mentioned tender no. for S. No. 35 has given with name & specification strength as Bortezumab 2.5 mg whereas we have Bortezumab 2 mg strength. Hence request you to please change item specification to Bortezumab 2 mg from 2.5 mg.	<b>Annexure 1</b> List of the item quoted NIT Sl no. 35 Bortezumab 2.5 mg Injection	No Change

3	M/s <b>Reliance Life Sciences</b>	<p>Following are the details regarding strength of Drug - Inj. Rituximab :- Product in Sr No.- 34, Inj. Rituximab 100 mg/vial(i) As per current available scientific studies the widely accepted and treating dose of Inj. Rituximab is starting from 375 mg/mt2 that is comes around approx. Inj. Rituximab 500 mg.(ii) As per our best of knowledge most of the Govt. Institutions, Railways and P.S.U. floating Tender of above mention tender with specification of Inj. Rituximab 500mg/vial. Kindly amend the Strength of Product in Sr No.- 34, Inj. Rituximab 100mg/vial to Inj Rituximab 500 mg/vial that is widely used and accepted does of drug in Kidney Transplant and other indication like Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) etc.</p>	<p><b>Annexure 1</b>List of the item quotedNIT SI no. 34 Rituximab 100 mg/vial</p>	No Change
---	--	--	--	-----------

4		NA	<p><b>24.QUALITY TESTING &amp; QUALITY CONTROL</b></p> <p>a) All the batches of the product supplied shall be supported by test/analysis reports furnished by independent NABL Accredited Drugs Testing Laboratory/Central Drug Testing Laboratory/In House Quality Control Laboratory. The TIA has the right to get the drugs tested at the laboratories of his choice for further verifications, from BMSICL empanelled laboratories.</p>	<p><b>QUALITY TESTING &amp; QUALITY CONTROL</b></p> <p>a) The TIA has the right to get the drugs tested at the laboratories of his choice for further verifications, from BMSICL empanelled laboratories.(i) All the batches of vaccines, serum, Immunologicals, blood products like Human Coagulation Factor VII, VIII, IX etc shall be supported by quality Clearance Certificate from CRI Kasauli/NIB Noida/Govt. Statutory Laboratories along with in House Quality Control Laboratory.(ii) All batches of Cold Chain items other than blood product shall be supported by quality Clearance certificate from CRI Kasauli/NIB Noida/Govt. Statutory Laboratories/Independent NABL Accredited Laboratories along with in house Quality Control Laboratory.(iii) For all batches of the products other than vaccines, serum, immunologicals, blood products and cold chain item shall be supported by quality Clearance certificate from CRI Kasauli/NIB Noida/Govt, Statutory Laboratory/ Independent NABL Accredited Laboratories/ In House quality control Laboratory.</p>
---	--	----	---	---

BMSIC/DRUGS/19-11 ANNEXURE-D						
PERFORMANCE STATEMENT						
(For the period of last three years)						
(Please furnish order copies of the client serially, the names of which are mentioned below)						
	Name of Bidder:			Name of the Item: (Performance statement for each quoted item in this format shall be submitted)		
	Name of Manufacturer:					
S. N.	Order placed by (Address of purchaser) (attach documentary proof) *	Order no. & Date	Order Quantity	Value of Contract (Rs.)	Date of Completion	Have the items been supplied satisfactorily (attach documentary proof) **
1						
2						
3						
4						
(Attach separate sheets if the space provided is not sufficient) * The documentary proof will be copies of the purchase order (during the last 3 years) indicating P.O. No. and date. ** The documentary proof will be certificate from the consignee/ end user indicating P.O. No. and date.						

**Authorized Signatory**

**Official Seal:**

**Date:**

**BMSIC/DRUGS/19-11**

**ANNEXURE-E**

**Production Capacity Statement (Self Declaration)**

S.N.	Pl. Mention Whether participating as a Manufacturer / Importer	Mfg. / Import license number/ product registration certificate of number	Validity of Mfg. / Import License, Validity of GMP/ COPP	Shelf life of the quoted item (s)	Standard Batch Size of the quoted item (s)	Monthly Production Capacity of the quoted item (s)	Annual Production Capacity of the quoted item (s)
1							
2							
3							
4							

Authorized Signatory

Official Seal:

Date

**ANNEXURE- C**

**LIST OF ITEMS QUOTED**

**Tender No.: BMSIC/DRUGS/19-11**

**Bidder Name:**

S. N.	Nit S N.	Name of the product	Specification / Strength & Unit Pack (As per approval obtained by the bidder from the competent authority)	Pl. Mention (Item wise) whether participating as a Manufacturer / Importer	Mfg. / import license number / product registration certificate number	Validity of Mfg. / Import License, Validity of GMP / WHO GMP /COPP	HSN CODE	Date of issue of product approval BY licensing authority	Shelf life of the quoted item(s)	Standard Batch Size of the quoted item(s)	Monthly Production Capacity of the quoted item(s)	Annual Production Capacity of the quoted item(s)
<b>1</b>												
<b>2</b>												
<b>3</b>												

**Date:**

**Seal:**

**(Authorized Signatory)**

**Name and Address of the Bidder with Stamp**